Rafael Holdings announced its financial results for Q4 and full fiscal year 2026, reporting a net loss of $9.2 million for Q4 and $29.6 million for the year, with reduced general and administrative expenses helping to lower losses. The company submitted a New Drug Application (NDA) to the FDA for remibetadex (Trappsol® Cyclo™), a treatment for Niemann-Pick Disease Type C, supported by Phase 3 trial data. Despite the Phase 3 study not meeting its primary endpoint in the overall population, a subgroup analysis showed significant slowing of disease progression. Rafael Holdings also advanced other projects, including a license for Alzheimer's treatment and a Phase II trial for head and neck cancer. The NDA submission marks a key regulatory milestone, with the FDA review and potential approval critical for the company's future prospects.
Rafael Holdings reported a net loss of $9.2 million in Q4 and $29.6 million for fiscal 2026, alongside a key NDA submission to the FDA for a Niemann-Pick Disease treatment. For readers following the health sector, here is Pluang's market snapshot as of Oct 29, 2026 18:11 WIB: out of 150 priced US health stocks, 95 rose and 47 fell. Notable movers include Novartis AG (NVS) at USD 160.96 with a 3.13% increase, Sana Biotechnology Inc (SANA) at USD 2.71 up 3.04%, and Gilead Sciences, Inc. (GILD) at USD 163.65 rising 2.80%.
Naples Comprehensive Health (NCH) has completed the first tricuspid valve repair in the US using the PASCAL Precision system following FDA approval. This minimally invasive catheter-based procedure offers a new treatment option for patients with seve...
Immunocore Holdings will present Phase 1/2 clinical trial data for brenetafusp alone and combined with KIMMTRAK in treating metastatic uveal melanoma at the 2026 Society for Immunotherapy of Cancer meeting. This trial evaluates safety and efficacy in...
Collegium Pharmaceutical and Boston Legacy FC have extended their partnership to include youth coach training, an annual Sports for All Summit, and sensory inclusion programs aimed at supporting neurodivergent children, especially those with ADHD, in...
Gilat Satellite Networks announced that its CEO Adi Sfadia and CFO Gil Benyamini will attend the Deutsche Bank Global Space and Defense Tech Summit on November 18, 2026, in New York City. The event will feature one-on-one and group meetings, providin...
Boralex Inc. has acquired Wind2, a UK-based renewable energy developer with about 350 MW of advanced wind projects across Scotland, England, and Wales. This acquisition strengthens Boralex's presence and capabilities in the UK, aligning with its stra...
